Evidence map›Paper›PMID 41744870›Full record

GuidelineCurrent oncology (Toronto, Ont.)2026

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025.

Katarzyna J Jerzak, Aalok Kumar, Jean-François Boileau, Nathaniel Bouganim, Christine Brezden-Masley, Jeffrey Q Cao, David W Cescon, Stephen Chia, Scott Edwards, Anil Abraham Joy and 9 more

Abstract readGuideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Katarzyna J JerzakSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.
Aalok KumarBC Cancer- Surrey, University of British Columbia, Vancouver, BC V3V 1Z2, Canada.
Jean-François BoileauJewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.
Nathaniel BouganimMcGill University Health Centre, McGill University, Montréal, QC H4A 3J1, Canada.
Christine Brezden-MasleyMarvelle Koffler Breast Centre, Mount Sinai Hospital, University of Toronto, Toronto, ON M5G 1X5, Canada.ORCID 0000-0002-4818-318X
Jeffrey Q CaoArthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N 4N1, Canada.
David W CesconPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.ORCID 0000-0002-1080-0998
Stephen ChiaBC Cancer-Vancouver, University of British Columbia, Vancouver, BC V5Z 4E6, Canada.
Scott EdwardsDr. H. Bliss Murphy Cancer Center, Memorial University of Newfoundland, St. John's, NL A1B 3V6, Canada.
Anil Abraham JoyCross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.ORCID 0000-0003-4201-8930
Kara LaingDr. H. Bliss Murphy Cancer Center, Memorial University of Newfoundland, St. John's, NL A1B 3V6, Canada.
Nathalie LeVasseurBC Cancer-Vancouver, University of British Columbia, Vancouver, BC V5Z 4E6, Canada.ORCID 0000-0002-2581-4903
Sasha LupichukArthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N 4N1, Canada.ORCID 0000-0001-9545-0802
Sandeep SehdevThe Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.ORCID 0000-0001-7434-2263
Christine SimmonsBC Cancer-Vancouver, University of British Columbia, Vancouver, BC V5Z 4E6, Canada.ORCID 0000-0002-6571-4587
Marc WebsterArthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N 4N1, Canada.
Karen A GelmonFaculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.ORCID 0000-0003-4111-2757
Mita MannaSaskatoon Cancer Centre, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada.ORCID 0000-0003-4344-7913
On Behalf Of Patient Advocacy Breast Cancer Canada

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for approximately two-thirds of all breast cancers. The treatment landscape for HR+/HER2- metastatic breast cancer has evolved in recent years, with multiple new therapies demonstrating clinical efficacy and improved patient outcomes. To provide evidence-informed guidance on best practices in the management of patients with HR+/HER2- metastatic breast cancer in Canada, consensus recommendations were developed by Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance), a standing nucleus committee with both clinical-academic oncologists from across Canada and representatives from Breast Cancer Canada, a patient advocacy organization. Recommendations were generated using a modified Delphi approach involving up to three anonymous voting rounds, with a predefined consensus threshold of 75%. These consensus recommendations offer guidance on optimal therapeutic strategies for HR+/HER2- metastatic breast cancer within the Canadian landscape, including integration of precision oncology and targeted therapies, optimal sequencing of therapies, and the importance of balancing the benefits of treatments with patient quality of life and preferences.

Indexed as

advancedbreast cancerCanadian consensus recommendationsevidence-basedHR+ HER2− metastaticREAL Alliance

Identifiers

PMID41744870
PMCPMC12938948

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.